TELA Bio: Upcoming Earnings Report Insights and Analysis

Author: Dylan Bailey Updated: 11-12-2025 11:33 AM

TELA Bio's Earnings Report: What to Anticipate

TELA Bio (NASDAQ: TELA) is anticipated to release its quarterly earnings soon, a significant event for investors wanting to understand the company's financial health and future prospects.

Expected Performance Metrics

Analysts predict that TELA Bio will report an earnings per share (EPS) of $-0.19. Expectations are high as the market eagerly awaits guidance on future performance.

Investors' Sentiments Prior to Announcement

The anticipation for TELA Bio's earnings release is palpable, especially with investors looking for signs that the company will not only meet or exceed these estimates but also provide an encouraging outlook for the upcoming quarter.

Insights from Previous Earnings Releases

In its last earnings release, TELA Bio fell short of expectations, reporting an EPS that was $0.04 below forecasts, which caused a notable decline of 13.98% in share price. Historical performance remains critical for investors as they prepare for the upcoming report.

Evaluating Past Results

Understanding previous earnings can help paint a clearer picture of where TELA Bio stands today. In the last four quarters, the trends have shown an EPS that fluctuates with missed targets potentially influencing share price trajectory:

Q2 2025: EPS Estimate: -0.18, Actual: -0.22, Price Change: -14.00%
Q1 2025: EPS Estimate: -0.23, Actual: -0.25, Price Change: +9.00%
Q4 2024: EPS Estimate: -0.22, Actual: -0.23, Price Change: -37.00%
Q3 2024: EPS Estimate: -0.40, Actual: -0.42, Price Change: +3.00%

TELA Bio's Current Share Price Evaluation

TELA Bio's shares were trading around $1.19 recently, a striking decrease of 61.84% over the past year, reflecting a challenging 12 months for shareholders as sentiment remains cautious. The decline in share price creates a tense environment going into the earnings announcement.

Long-Term Shareholder Concerns

Long-term investors have often been let down by the company's inability to stabilize its financial metrics. As they prepare for the upcoming earnings, their disappointment from prior trends may influence market reactions.

Investor Takeaway and Conclusion

Considerably, TELA Bio's performance hinges on both the EPS report and the subsequent guidance it provides. Investors should keep an open mind, analyzing both numbers for a comprehensive understanding of the company's trajectory moving forward into the next quarter.

Frequently Asked Questions

What is TELA Bio's expected EPS for the upcoming earnings report?

The expected EPS for TELA Bio in the upcoming earnings report is $-0.19.

How did TELA Bio perform in its last earnings release?

In its last earnings release, TELA Bio missed EPS estimates by $0.04, resulting in a 13.98% drop in share price.

What is TELA Bio's current stock price?

TELA Bio's shares were trading at approximately $1.19 recently.

How has TELA Bio’s stock performed over the last year?

Shares of TELA Bio have decreased by about 61.84% over the last 52 weeks.

What factors should investors consider before the earnings release?

Investors should consider both past performance metrics and any guidance provided by TELA Bio for future quarters, as these can significantly impact market reactions.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.